Dr. Christian Höftberger appointed new CEO of RHÖN-KLINIKUM AG
At its meeting today, the Supervisory Board of RHÖN-KLINIKUM AG has unanimously appointed Dr. Christian Höftberger (46)…
At its meeting today, the Supervisory Board of RHÖN-KLINIKUM AG has unanimously appointed Dr. Christian Höftberger (46)…
Management Board of RHÖN-KLINIKUM AG extended by two members in the course of strategic partnership with Asklepios Klini…
The Management Board of RHÖN-KLINIKUM AG welcomes the new partnership with Asklepios Kliniken GmbH & Co. KGaA. The volun…
. - Christina Triantafyllou, Ph.D., was nominated for the award along with Professor Arnd Dörfler, M.D., Head of Univers…
3-year-partnership contract signed, extending to June 30, 2020 Siemens Healthineers providing the soccer club with…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
. - Baseline and biomarker characteristics of advanced HCC patients identified that have an impact on overall survival…
. - The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone…
. - Data from completed Phase I part of SHORE study in advanced colorectal cancer (CRC) to be presented at upcoming ASC…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoim…